HLS Therapeutics Inc. (HLS.TO) TSX
4.44
-0.01(-0.22%)
Currency In CAD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.44
-0.01(-0.22%)
Currency In CAD
Address
10 Carlson Court
Etobicoke, ON M9W 6L2
Canada
Phone
647-495-9000
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
92
First IPO Date
March 14, 2018
| Name | Title | Pay | Year Born |
| Craig Stuart Millian | Chief Executive Officer & Director | 1.27M | 1968 |
| Jason A. Gross | Vice President of Scientific Affairs | 400,775 | 1965 |
| Ryan C. Lennox | Senior Vice President of Legal, HR & Compliance and Corporate Secretary | 508,780 | 1981 |
| Brian T. Walsh | Chief Commercial Officer | 618,160 | N/A |
| John Hanna | Chief Financial Officer & Non-Independent Director | 662,140 | 1965 |
| Dave Mason | Investor Relations Officer | 0 | N/A |
| David Spence | Vice President & Corporate Controller | 0 | 1968 |
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.